Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Liver Cancer treatment details. Biologic therapy. Memorial Sloan-Kettering Cancer Center, New York, N.Y., United States

Survival: 9.2 months
Toxicity Grade: 3
Treatments: Biologic therapy
Country: United States
City/State/Province: New York, N.Y.
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 9/2006

Patients: This phase II study involved 137 patients with inoperable liver cancer that had not received a systemic treatment. The median age was 69 years, and 71% were men. Sixty-five had hepatitis B or C.

Treatment: All patients received the drug Sorafenib, which inhibits multiple kinases.

Toxicity: The most common toxicities (of all grades) were fatigue, diarrhea, and hand-foot skin reaction. These were grade 3 adverse events in 13, 11, and 7 patients, respectively.

Results: The median overall survival was 9.2 months.

Support: Four of the authors are employed by Bayer Healthcare Pharmaceuticals, and two received research funds from Bayer. Bayer developed Sorafenib.

Correspondence: Ghassan K. Abou-Alfa, M.D.

E-mail to a Friend Email Physician More Information